Stockscreener 앱 받기
71.65
0.47%
-0.34
시장 영업 전:
71.15
-0.50
-0.70%
Disc Medicine Inc 주식(IRON)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
getLinesFromResByArray error: size == 0 - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Hedge Fund Bets: Whats the beta of Disc Medicine Inc stockJuly 2025 Action & Entry Point Confirmation Alerts - baoquankhu1.vn
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
Trend Review: Will Disc Medicine Inc outperform during market rallies2025 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Responsive Playbooks and the IRON Inflection - Stock Traders Daily
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BMO Capital reaffirms Disc Medicine stock rating amid approval optimism By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Investors to Inquire about Securities Investigation - accessnewswire.com
Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade - Yahoo Finance
Disc Medicine, Inc. (IRON) Stock Analysis: Biotech Innovator With A 57% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Investors to Reach Out - ACCESS Newswire
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst - streetwisereports.com
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON - Chartmill
Bear Alert: What is Disc Medicine Inc. s debt to equity ratioJuly 2025 Catalysts & Accurate Intraday Trade Tips - baoquankhu1.vn
HC Wainwright Weighs in on Disc Medicine FY2030 Earnings - MarketBeat
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
iA Global Asset Management Inc. Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Understanding the Setup: (IRON) and Scalable Risk - Stock Traders Daily
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock - MarketBeat
The Bull Case For Disc Medicine (IRON) Could Change Following FDA Review Delay And New HR Chief Appointment - Sahm
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Is Disc Medicine Inc. attractive at current valuationWeekly Market Outlook & High Win Rate Trade Alerts - bollywoodhelpline.com
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus - Sahm
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON) - The Globe and Mail
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA ActionDisc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
Reported delays to FDA reviews under new fast-track program - The Pharma Letter
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com South Africa
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨 - XTB.com
Disc Medicine (IRON) Shares Decline as FDA Review Faces Brief De - GuruFocus
1.24%
0.19%
자본화:
|
볼륨(24시간):